Maverick Capital Ltd. Boosts Position in DaVita Inc. (NYSE:DVA)

Maverick Capital Ltd. boosted its position in shares of DaVita Inc. (NYSE:DVA) by 168.4% during the second quarter, Holdings Channel reports. The firm owned 11,553 shares of the company’s stock after buying an additional 7,248 shares during the quarter. Maverick Capital Ltd.’s holdings in DaVita were worth $1,601,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of DVA. Norges Bank purchased a new stake in DaVita during the fourth quarter worth $36,626,000. Franklin Resources Inc. boosted its position in DaVita by 42.0% during the fourth quarter. Franklin Resources Inc. now owns 7,866 shares of the company’s stock worth $824,000 after purchasing an additional 2,325 shares in the last quarter. Advisory Services Network LLC purchased a new stake in DaVita during the fourth quarter worth $385,000. Nomura Asset Management Co. Ltd. lifted its position in shares of DaVita by 1.1% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 29,375 shares of the company’s stock valued at $3,077,000 after acquiring an additional 331 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of DaVita by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 24,737 shares of the company’s stock valued at $2,591,000 after acquiring an additional 234 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DVA shares. Truist Financial upped their price objective on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. TD Cowen upped their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. UBS Group upped their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Bank of America upped their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $157.00.

DaVita Stock Performance

NYSE DVA opened at $163.09 on Friday. The business’s 50-day moving average price is $150.14 and its 200 day moving average price is $142.09. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $166.04. The company has a market capitalization of $14.30 billion, a PE ratio of 18.53, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the prior year, the business posted $2.08 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, research analysts predict that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.